Fig. S1




Fig. S2 All patients included in the analysis (n = 317)




Fig. S3 Asymptomatic patients at the initial pouchoscopy (n = 119)




Fig. S4





Fig. S5



All patients included in the analysis (n = 376)b C Pouch failure-free survival 25% 25% 25% Pouch failure-free survival Pouch failure-free survival 75% p = 0.06775% p = 0.2650% 50% Afferent limb involvement 25% All patients included in the analysis (n = 376) 0% 8 10 12 14 16 18 20 6 8 10 12 14 16 18 20 6 8 10 12 14 16 18 Time after the date of 1st scope (years) Time after the date of 1st scope (years) Time after the date of 1st scope (years) d е Pouch failure-free survival Pouch failure-free survival Pouch failure-free survival 75% p = 0.0008275% p = 0.975% p = 0.3850% 50% 50% Diffuse inflammation of the pouch body Focal inflammation of the pouch body 25% 25% 8 10 12 14 16 18 20 8 10 12 14 16 18 20 10 12 14 16 18 20 Time after the date of 1st scope (years) Time after the date of 1st scope (years) Time after the date of 1st scope (years) g h Pouch failure-free survival Pouch failure-free survival Pouch failure-free survival p = 0.7275% 75% p = 0.7575% p = 0.1150% 50% 50% Number of phenotype at the first scope 25% 25% 2 4 6 8 10 12 14 16 18 20 Time after the date of 1st scope (years) 8 10 12 14 16 18 20 8 10 12 14 16 18 20 Time after the date of 1st scope (years) Time after the date of 1st scope (years)

Fig. S7 Asymptomatic patients at the initial pouchoscopy (n = 121)




Fig. S8




Fig. S9




Fig. S10

